Travere Therapeutics' Amortization of Deferred Charges fell 85.17% to $428,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $1.6 million, marking a year-over-year decrease of 85.57%. This contributed to the annual value of $1.7 million for FY2024, which is 0.41% up from last year.
Per Travere Therapeutics' latest filing, its Amortization of Deferred Charges stood at $428,000 for Q4 2022, which was down 0.00% from $428,000 recorded in Q3 2022.
In the past 5 years, Travere Therapeutics' Amortization of Deferred Charges ranged from a high of $2.9 million in Q4 2021 and a low of $325,000 during Q2 2018.
Moreover, its 3-year median value for Amortization of Deferred Charges was $2.6 million (2020), whereas its average is $1.9 million.
In the last 5 years, Travere Therapeutics' Amortization of Deferred Charges spiked by 1,133.67% in 2018 and then plummeted by 87.65% in 2022.
Travere Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $2.4 million in 2018, then climbed by 3.64% to $2.5 million in 2019, then increased by 7.30% to $2.7 million in 2020, then grew by 7.33% to $2.9 million in 2021, then tumbled by 85.17% to $428,000 in 2022.
Its Amortization of Deferred Charges was $428,000 in Q4 2022, compared to $428,000 in Q3 2022 and $428,000 in Q2 2022.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value